

April 1, 2021

## Patient Access Network Foundation

### PROGRAM REVIEW

Prepared by:

Brian Annulis and Christopher Tonellato  
Ankura Consulting Group, LLC  
1801 W. Warner Avenue, Suite 103  
Chicago, IL 60613

## **Introduction**

Patient Access Network Foundation (“PAN” or the “Foundation”) engaged Ankura Consulting Group, LLC (“Ankura”) to complete an annual Program Review as is required by PAN’s Standard Donation Agreement (“Donation Agreement”). More specifically, PAN engaged Ankura to serve as the Independent Review Organization (“IRO”), as required by Section 1 in Exhibit A of the Donation Agreement. This report (the “Program Review Report” or “Report”) addresses the requirements in Exhibit A related to PAN’s Disease Fund systems, processes, policies and practices.

## **General Review Limitations**

Our review procedures were limited to those described in this Report. We relied on documentation supplied to us by PAN without any independent verification. Had we performed additional procedures, other matters might have come to our attention that may have impacted our findings and recommendations. The procedures we performed do not constitute an “examination” or “review,” as those terms are defined by the American Institute of Certified Public Accountants. We performed no procedures to evaluate the reliability or completeness of the information provided.

## **Credentials of Individuals who Performed the Program Review**

The Program Review was conducted by Brian Annulis and Christopher Tonellato.

Brian Annulis is a Senior Managing Director at Ankura with more than 25 years of experience helping clients successfully manage complex healthcare compliance and regulatory concerns. He has expertise assisting organizations with developing, implementing, maintaining, and assessing compliance programs, and in managing matters implicating the Stark Law and the federal Anti-Kickback Statute. He also assists organizations with data privacy and security concerns. He is based in Chicago.

Brian has spent his entire professional career counseling and advising healthcare providers, suppliers, practitioners, manufacturers, and health plans. Having served as a former attorney for the Centers for Medicare & Medicaid Services, Brian is well-informed in matters affecting healthcare entities. In addition, he has significant experience in matters involving health information and data privacy.

Chris Tonellato is a Senior Associate at Ankura, where he focuses primarily on healthcare compliance, clinical research billing, and privacy regulation. He is based in Chicago.

Prior to joining Ankura, Chris worked for a large law firm's healthcare practice group and two different Chicago area hospitals, supporting their legal teams with various regulatory, transactional, and compliance projects. Chris graduated from Loyola University Chicago School of Law with certificates in both compliance and health law. He served as a lead article editor for the Loyola University Chicago Law Journal and as a fellow at the Beazley Institute for Health Law and Policy

### **Program Review Analysis:**

As described in Exhibit A of the Donation Agreement, Ankura conducted the Program Review to assess and evaluate PAN's systems, processes, policies and practices related to their Disease Fund Programs. This assessment and evaluation included an examination of the following parameters.

#### **I. The Foundation is a bona fide, non-profit organization that serves the interests of patients with particular diseases or conditions.**

##### Review Methodology:

Ankura reviewed PAN's original IRS 501(c)(3) Application Form, 501(c)(3) Determination Letter, and PAN's 2019 IRS Form 990 when evaluating this parameter. This included a review of the public charity test in the IRS Form 990 and the proportion of donations provided by the general public.

##### Evaluation:

PAN is a bona fide, non-profit, tax exempt organization and classified by the IRS as a 501(c)(3) public charity. As of 2019 (the most recently available Form 990), PAN receives funding from a variety of sources including more than 50 corporate donors and over 1,000 individual donors. PAN qualifies for public charity status using the 10% facts and circumstances test as described by 170(b)(1)(A)(vi) of the Internal Revenue Code. In 2019, PAN received 30% of its support from the public.

PAN's mission is: "To help underinsured people with life-threatening, chronic and rare diseases get the medications and treatments they need by assisting with their out-of-pocket costs and advocating for improved access and affordability."

**II. The Foundation is independent of any donor to the Program, including Donor (collectively, the "Program Donors"). For purposes of determining independence, inter alia, no members of the Foundation's governing body will be employed by a Program Donor.**

Review Methodology:

Ankura reviewed PAN's Conflict of Interest ("COI") Policy and Conflict of Interest Standard Operating Procedure to ensure it adhere to the standards set by the Office of Inspector General ("OIG") of the Department of Health and Human Services Advisory Opinion 07-18 (as modified) ("AO" or "Advisory Opinion") and the Integrity Agreement entered into by and between the OIG and PAN (the "IA"). The review also included all COI disclosure forms submitted by PAN's board Members as well as any follow-up questions or correspondence required to clarify disclosed potential COIs.

Ankura also reviewed PAN's Policies and Standard Operating Procedures ("SOP") related to PAN's independence from donors including the Donor Communication Guidelines, Donor Communication Policy, Establishing New Disease Funds SOP, Identifying New Disease Funds SOP, and Disease Fund Definition SOP.

Evaluation:

In 2020, PAN received and reviewed all COI Disclosure Forms as were required by its COI Policy and SOP. All directors, committee members and employees are required to follow the COI Policy and annually report any COIs that they may have.

No members of PAN's Board of Directors reported being employed by a Program Donor. One Board member reported that they may receive compensation from a potential donor as a result of the potential donor being a client of that Board member. As required by policy, PAN requested additional details from the Board member. No evidence existed that an actual COI existed. If there was a COI, the Board member would have been required to recuse himself from any Board meeting and take no part in discussions and decisions related to any transaction or arrangement in which he may be perceived to have a COI.

PAN's Policies and SOPs ensure it remains independent of any Program Donor and maintains compliance with the independency requirements described in its Advisory Opinion, IA, and other relevant guidance from the OIG. Donor and potential donors are prohibited from making recommendations or suggestions regarding the design or creation of a new or existing disease fund.

**III. The Program receives referrals from a number of sources, including physicians, suppliers, patient advocacy groups, and other relevant sources.**

Review Methodology:

During discussions between Ankura and PAN, PAN confirmed that it does not track referral sources. Ankura reviewed PAN's Patient Assistance Policy and the Disease Fund New Enrollment SOPs to evaluate whether referrals may be tracked or recorded. In addition, documentation from a sample of 24 applications from CY 2020 was reviewed to evaluate how the Policy and SOP are implemented. PAN's marketing and advertising plan was reviewed to evidence that PAN makes a concerted effort to promote its programs to numerous sources.

Evaluation:

PAN allows applications to be submitted by patients, their caregivers, providers, and pharmacies. Applications may be submitted to PAN's Call Center, Website, or Portals. In doing so, PAN does not track or record any potential referral source because it plays no role in the applicant's eligibility. As such, there is no way to know the demography of referral sources. This was verified by the review of sample patient applications. However, PAN makes a significant effort to promote its programs to a broad range of potential applicants. PAN's marketing and advertising efforts include:

- Promoting assistance programs on PAN's website and the FundFinder website;
- Promoting programs and disseminating PAN's educational and advocacy resources through newsletters and email communications;
- Collaborating with other patient assistance organizations as alliance partners;
- Promoting its programs and educational materials through social media and YouTube;
- Publishing op-eds and providing media interviews when requested;

- Publishing matte releases to educate consumers about lowering their out-of-pocket medications costs and assistance PAN can provide; and
- Attending and speaking at various conferences.

**IV. The Foundation's determination of whether to provide assistance does not consider the source that referred the patient to the Program.**

Review Methodology:

During discussions between Ankura and PAN, PAN confirmed that it does not track referral sources. Ankura reviewed PAN's Patient Assistance Policy, Disease Fund New Enrollment SOP, Grant Renewal SOP, Second Grant SOP, and Disease Fund Wait List SOP to evaluate whether or not the referral source is used as a criteria of eligibility for patients applying to assistance. In addition, documentation from a sample of 24 applications from CY 2020 was reviewed to evaluate how the Policy and SOPs are implemented.

Evaluation:

PAN never considers a referral source when determining a patient's eligibility for assistance. An applicant's eligibility is determined using PAN's established criteria including the following for all assistance programs:

- The patient must be getting treatment for the disease named in the assistance program to which he or she is applying.
- The patient must have health insurance that covers his or her qualifying medication or product.
- The patient's medication or product must be listed on PAN's list of covered medications.
- The patient's income must fall at or below the Federal Poverty Level specified by the assistance program.
- The patient must reside in and be receiving treatment in the U.S. or its territories. (U.S. citizenship is not a requirement.)

The review of sampled applications demonstrated that when patients apply for assistance from PAN, referral source is not a factor when determining an applicant's eligibility.

**V. The Foundation bases all financial eligibility determinations on its own established criteria and does not take into account the identity of a provider, supplier or treatment that the patient may use or the identity of a Program Donor whose services or products are used by the applicant.**

Review Methodology:

Ankura reviewed PAN's Policies and Standard Operating Procedures ("SOP") related to PAN's independence from donors including the Patient Assistance Committee ("PAC") Charter, Donor Communication Guidelines, Donor Communication Policy, Establishing New Disease Funds SOP, Identifying New Disease Funds SOP, and Disease Fund Definition SOP. Ankura also reviewed PAN's Conflict of Interest ("COI") Policy and Conflict of Interest Standard Operating Procedure, and the COI disclosure forms completed by PAN's Board Members.

The Patient Rights Policy, Patient Assistance Policy, Disease Fund New Enrollment SOP, Grant Renewal SOP, Second Grant SOP, and Disease Fund Wait List SOP were also reviewed to evaluate the requirement for patients to meet the financial eligibility criteria.

A sample of seven (7) disease funds were evaluated to ensure their creation and continued operation are conducted independent from donor influence. From these seven (7) sampled funds, 24 patient applications were sampled in order to evaluate their compliance with PAN's Policies and SOPs.

Evaluation:

The PAC, a standing committee of PAN's Board, is responsible for setting policies concerning patient eligibility requirements, the disease funds served, and program requirements of the disease funds. The policies and eligibility criteria must be set in compliance with the Advisory Opinion, the IA, and other applicable guidance, regulations, and laws.

Applicants are required to meet PAN's financial eligibility criteria for each program which is set at either 400% or 500% of the federal poverty line ("FPL"). Patients are screened for income eligibility before they are approved for a new grant and at minimum every year following if they apply for renewal grants. The parameters of eligibility start at 400% FPL for new disease funds and may increase to 500% FPL if PAN re-evaluates the level after a year.

PAN's financial eligibility criteria are approved by the PAC when the disease fund is created and may be reviewed for modification by the PAC if needed. Documentation from each of the sampled disease funds demonstrates the financial eligibility was set for the fund pursuant to PAN's Policies and SOPs and that the PAC reviewed and approved of the funds creation independent from any donor or potential donor influence.

A review of PAN's application process, including the sampled applications demonstrated that applicants are screened based on the fund's approved criteria and the various providers, suppliers, and treatments do not affect the determination of eligibility.

**VI. Assistance is available to financially needy beneficiaries who meet the Foundation's income and/or asset criteria, for a period of up to one (1) year, after which each beneficiary's eligibility is reevaluated.**

Review Methodology:

A review of PAN's Policies and SOPs was conducted, including the Patient Assistance Policy, Disease Fund New Enrollment SOP, Grant Renewal SOP, Second Grant SOP, and Disease Fund Wait List SOP.

In addition, Ankura reviewed PAN's application process by sampling 24 applications from CY 2020 and reviewing their application record and supporting documentation. A virtual walkthrough of the application system was also provided by PAN to demonstrate how PAN's system conducts the eligibility screening and to show how the eligibility period is tracked.

Evaluation:

As described above in Section V, PAN provides assistance to financially eligible individuals based on established parameters. When applying, a patient is required to self-attest to their income in order to meet this requirement. PAN's system uses an automated check to verify this reported income. If an issue is flagged, applicants are conditionally approved and must submit additional documentation or verification to prove they are financially eligible. This process must be repeated at minimum once a year in order for a patient to continue to be financially eligible.

The review of sample applications and the virtual walkthrough verified that applicants are required to meet the disease fund's financial eligibility criteria. Several of the sampled applications demonstrated the financial audit process when a patient's eligibility could not be automatically verified.

Fourteen (14) patient applications were randomly selected in order to test the income verification audit process. Each time the process worked correctly, and the patient was either approved after providing verification of their financial eligibility or denied after failing to do so in a timely manner. If the documentation showed the patient was above the FPL limit, they were removed from being conditionally approved and denied assistance. This review also demonstrated that all approved applicants had an eligibility period of one calendar year



from the date they were approved. If funding were available, the patient has the option to renew their grant, but their income would be re-verified prior to approval of a renewal.

**VII. Patient requests for assistance under the Program are reviewed on a first-come, first-served basis to the extent funding is available.**

Review Methodology:

Ankura reviewed PAN's Policies and SOPs including the Patient Assistance Policy, Disease Fund New Enrollment SOP, Grant Renewal SOP, Second Grant SOP, and Disease Fund Wait List SOP.

In addition, Ankura reviewed PAN's application process by sampling 24 applications from CY 2020 and reviewing their application record including their application date, eligibility start date, and eligibility end date. A report of the waitlists from five (5) of the seven (7) sampled disease funds was also reviewed to ensure compliance with this parameter.

Evaluation:

PAN ensures patients are provided assistance on a first-come, first-served basis when funding is available. If funding for a particular fund is exhausted, an applicant has the option to join the fund's wait list. The wait list is also maintained on a first-come, first-served basis. When a fund receives additional funding and can open to waitlisted applicants the approved applicants receive funding in the order that they were added to the wait list.

Two of the seven sample funds were open during the entirety of CY 2020 and therefore had no waitlist to review. The other five funds all maintained a waitlist which demonstrated applicants were placed on the list and provided funding on a first-come, first-served basis.

**VIII. The Foundation informs patients that they are free to change providers, suppliers or treatments at any time and will not lose their assistance as a result (unless they become ineligible for other reasons).**

Review Methodology:

Ankura reviewed PAN's Patient Rights Policy, Patient Assistance Policy, and Disease Fund New Enrollment SOP to evaluate if patients are free to change providers, suppliers, or treatments. To test that these Policies and Procedures were effective in operation, 24 sampled applications from CY 2020 were reviewed.

Evaluation:

PAN's Patient Rights Policy, Patient Assistance Policy, and Disease Fund New Enrollment SOP detail that recipients of assistance have freedom of choice regarding their products, practitioners, providers, suppliers, insurance companies, and treatment regimens. PAN does not refer to, recommend, or arrange for the use of any particular product, practitioner, provider, supplier, or insurance plan.

The review of PAN's application and screening process, including viewing several sampled applications, demonstrated that applicants have various providers, suppliers, and treatments and PAN does not make its eligibility decisions on that basis. In addition, a review of the template letter sent to approved applicants and copies of actual letters sent to sampled approved applicants shows that patients all receive the following language:

Assistance through the Patient Access Network (PAN) Foundation is not tied to any doctor or healthcare provider, treatment or pharmacy that you are currently using. You have the right to choose any healthcare provider, treatment or pharmacy covered by your insurance plan and associated with your disease, and you may change any of these during your eligibility period without any effect on your assistance through the PAN Foundation (as long as you continue to meet the set eligibility criteria). If there are any changes to the treatment you have been prescribed, your healthcare provider, your insurance status, your financial situation or your medical condition (as it relates to your disease), please contact the PAN Foundation so we can update your records.

**IX. The Foundation does not refer patients to, or recommend, a particular provider, supplier or product.**

Review Methodology:

Ankura reviewed PAN's Patient Rights Policy, Patient Assistance Policy, and Disease Fund New Enrollment SOP to evaluate if PAN ever refers patients to particular providers, suppliers, or products. To test that these Policies and Procedures were effective in operation, we reviewed 24 sampled applications from CY 2020.

Evaluation:

As described in more detail in Section VIII above, PAN does not refer to, recommend, or arrange for the use of any particular product, practitioner, provider, supplier, or insurance plan.

No evidence was found in the sampled applications that PAN makes a referral to a particular provider, supplier, or product. Patients are notified they have the right to choose their own provider, supplier, or product.

**X. The Foundation does not inform patients of the identities of Program Donors.**

Review Methodology:

Ankura reviewed PAN’s Donor Communication Guidelines, Donor Communication Policy, Disease Fund Enrollment SOP, and Inbound Call Management SOP to evaluate this parameter. PAN also provided Ankura a virtual walkthrough of the patient application process to demonstrate compliance. Lastly, Ankura reviewed a sample of 24 patient applications from CY 2020 to review communications from PAN to the patients.

Evaluation:

PAN’s policies and SOPs ensure that donor information, including the identity of Program Donors is not made available to the public. Additionally, this information is not available to applicants when applying for assistance or when they are approved for assistance. Call center employees have no details on donors and therefore can never provide patients the identity of Program Donors.

To evidence this, a review of the communications and welcome letters from the sampled patient applications found that they did not contain any donor information. Templates PAN uses for those letters also do not contain any donor information. In addition, when a walkthrough of the application process was provided and after reviewing PAN’s website, no information is provided to identify the Program Donors.

**XI. To the extent feasible, the Foundation furnishes assistance under the Program to the provider, supplier or insurer on behalf of the patient, and where assistance is furnished directly to the patient, the Foundation obtains proof from the patient that the assistance is to satisfy qualifying expenses.**

Review Methodology:

Ankura reviewed PAN’s Assistance Program Parameter Management SOP and Grant Allocation Model SOP to evaluate this parameter.

Evaluation:

PAN provides assistance for products directly to providers and pharmacies when applicable. Patients may be reimbursed directly if they incur the costs or in the case of some premium assistance programs. PAN verifies the patient’s expenses and obtains proof from the patient

for qualifying expenses or requires proof of premium payment from an insurance statement, employer paystub, COBRA statement, or Social Security statement with Medicare premium. If a patient is unable to provide documentation, the premium cost must be obtained verbally and validated with the insurance company.

**XII. The Foundation has a process to solicit donations for the Program from a multitude of sources.**

Review Methodology:

Ankura reviewed PAN's Donor Communication Guidelines, PAN's Development Gameplan: Donors and Disease Fund Tracker, and PAN's public facing guidance and information available for individuals and others to use when considering donating to PAN. Details from PAN's 2019 IRS Form 990 were also reviewed to evaluate this parameter.

Evaluation:

PAN's policies and procedures demonstrate PAN's commitment to obtaining funding from multiple donors and sources to fulfil the patient need. PAN's Donor Communications Guidelines ensure donors and potential donors are aware of the restraints and requirements when communication with PAN regarding a donation or development of a disease fund. PAN does not solicit, nor will it accept recommendations or suggestions from donors regarding the creation or modification of a new or existing disease fund.

PAN's public website contains a page titled "Ways to Give" which describes the various ways individuals and other entities may donate to PAN. PAN solicits donations from a multitude of sources including more than 50 corporate donors and over 1,000 individual donors since 2015 according to PAN's 2019 IRS Form 990. In 2019, 30% of its support from the public, demonstrating PAN's solicitation to various sources is successful. PAN develops and maintains a Development Gameplan it uses to track the development of disease fund donations from multiple donor sources. This demonstrates PAN's commitment to soliciting donations for a disease fund program from multiple sources.

**XIII. The Foundation uses commercially reasonable efforts to publicize the availability of the Program to patient advocacy organizations, other relevant third parties and patients.**

Review Methodology:

Ankura requested PAN provide a summary of all marketing and advertising materials used in CY 2020. Ankura reviewed the summary provided as well as the available communications,

articles, and websites to evaluate PAN's efforts to publicize its disease funds to patients, patient advocacy groups, and other relevant third parties.

Evaluation:

PAN puts significant effort into publicizing all of its disease funds and assistance programs to patients, patient advocacy organizations, providers, pharmacies, and other relevant third parties. PAN's quarterly newsletters to providers, pharmacies, donors, and the patient advocacy community regularly provide important updates regarding new funds that may be available and any changes to existing funds when applicable. In addition, some of PAN's other publicization efforts include the following:

- Promoting assistance programs on PAN's website and the FundFinder website;
- Promoting programs and disseminating PAN's educational and advocacy resources through newsletters and email communications;
- Collaborating with other patient assistance organizations as alliance partners;
- Promoting its programs and educational materials through social media and YouTube;
- Publishing op-eds and providing media interviews when requested;
- Publishing matte releases to educate consumers about lowering their out-of-pocket medications costs and assistance PAN can provide; and
- Attending and speaking at various conferences.

***The Foundation otherwise complies with the requirements of OIG Advisory Opinion 07-18 (as modified).***

The Advisory Opinion outlines many requirements PAN must follow when creating and maintaining its Disease Fund programs. Many of these requirements are functionally similar or identical to the parameters discussed above and have been considered as part the described assessment and evaluation. The following are the remaining assessed and evaluated requirements from the Advisory Opinion.

**XIV. PAN may establish minimum claim amounts if motivated by a desire to reduce administrative expenses but must allow patients to aggregate claims to reach the minimum threshold.**

Review Methodology:

Ankura reviewed PAN’s Assistance Program Parameter Management SOP as well as the “Minimum Claim Requirement per disease fund” section of PAN’s internal Contact Center webpage which was furnished to Ankura. The information reviewed from the Contact Center detailed which funds currently have claim threshold limits and which funds had a limit in CY 2019.

Evaluation:

As of January 2, 2020, none of PAN’s disease funds or assistance programs have a claim minimum threshold. In 2019, only two disease funds had claim minimum thresholds of \$25 and \$50, respectively. When a minimum threshold exists for a fund, individual claims or prescriptions may be combined or aggregated and then submitted in order to reach the minimum. Any fund minimum thresholds are reviewed annually by PAN.

PAN’s Assistance Program Parameter Management SOP describes this process and these requirements. When minimum claim thresholds exist, they must be publicized to all patients enrolled in the assistance program.

**XV. Cost-sharing grants must be paid directly to physicians, providers, suppliers, insurance companies, or in cases where third-party payment is not accepted, to the patient, upon proof that the patient incurred the costs.**

Review Methodology:

Ankura reviewed PAN’s Assistance Program Parameter Management SOP and Grant Allocation Model SOP to evaluate this parameter.

Evaluation:

PAN’s Premium Assistance Support SOP describes the process of paying for or reimbursing patient’s premium’s amounts. PAN verifies the patients costs and requires proof of premium payment from an insurance statement, employer paystub, COBRA statement, or Social Security statement with Medicare premium. If a patient is unable to provide documentation, the premium cost must be obtained verbally and validated with the insurance company.

**XVI. PAN Board members and officers may not have any financial relationship with the Administrator or any of its affiliates.**

Review Methodology:

Ankura reviewed PAN's Conflict of Interest ("COI") Policy, Conflict of Interest Standard Operating Procedure, and all Board Members COI Disclosure Forms, including any follow-up questions or correspondence related to disclosed COIs or potential COIs.

Evaluation:

In 2020, PAN's Administrator, as described in the AO, was CareMetx. None of PAN's Board member's COI Disclosure Forms showed any financial relationship or COIs with CareMetx.

**XVII. PAN and its Administrator must ensure that the Administrator's ethical wall separating its PAN operations from its pharmaceutical company services, as well as specified Administrator safeguards ensuring against any improper influence by Administrator clients, are implemented and maintained properly. PAN and the Administrator must maintain up-to-date records pertaining to the Administrator's ethical wall and safeguards ensuring against improper influence by Administrator clients.**

Review Methodology:

Ankura was unable to view the CareMetx office space in person due to safety concerns during the COVID-19 pandemic; however, we were able to review the floorplans, office layout, and seating chart to evaluate the physical aspects of CareMetx' ethical wall. The Master Services Agreement between PAN and CareMetx details and describes several aspects of the physical, data, and ethical wall requirements. PAN also furnished copies of the Compliance Training materials CareMetx employees must complete when working for PAN. The logs and certifications of completion from CY 2020 were also furnished for our review.

Additionally, virtual meetings between Ankura, PAN, and PAN dedicated CareMetx staff provided supplemental details and understanding of the ethical wall maintained between CareMetx' other operations and the PAN operations at CareMetx.

Evaluation:

The review of PAN and CareMetx' relationship showed that PAN maintains a comprehensive physical, electronic, and ethical wall between PAN staff and other CareMetx staff who do not work for PAN. CareMetx staff dedicated to PAN work exclusively for PAN and do not work

for any other CareMetx clients. These PAN dedicated CareMetx employees are physically separated from other CareMetx staff in their office and have different security card access.

The computer and phone systems used by PAN's CareMetx staff are separate and distinct from other CareMetx' systems to ensure no data is inadvertently transferred among CareMetx's clients. In addition, these staff are required to complete PAN's compliance training and sign PAN's Code of Conduct and Ethics.



## Exhibit A

### Documents Reviewed

1. 501(c)(3) Application Form
2. 501(c)(3) Determination Letter
3. PAN's 2019 Form 990
4. Conflict of Interest Policy
5. Board COI Review Summary
6. Email Correspondence regarding Board Member's reported COI
7. All Board Member's COI Disclosure Forms
8. PAN Foundation Marketing and Advertising Program 2020
9. Copies of Newsletters and Emails sent as part of the Marketing and Advertising
10. Patient Rights Policy
11. Disease Fund New Enrollment SOP
12. Patient Assistance Policy
13. Assistance Program Parameter Management SOP
14. Grant Renewal SOP
15. Disease Fund Wait List SOP
16. Second Grant SOP
17. Template Welcome Letter
18. Donor Communication Policy
19. Report of claims administered from Sampled Disease Funds
20. Donor Communication Guidelines
21. Development Gameplan: Donors and Disease Fund Tracker
22. Ways to Give webpage
23. Assistance Program Parameter Management SOP
24. Minimum Claim Requirement per disease fund - PAN Foundation Contact Center
25. Premium Assistance Support SOP
26. CareMetx MSA
27. CareMetx Floorplans
28. CareMetx – PAN Org Chart
29. CareMetx Compliance Training Slides
30. CareMetx Compliance Training Logs and Attestations for 2020
31. Underlying documentation from 24 patient applications
32. PAC Charter
33. PAC Policy
34. PAC Approvals for seven sampled disease funds